1:1 HbS Adducts Inhibit Sickle Cell Toxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for sickle cell disease, mediated by sickle hemoglobin (HbS), require high doses of five-membered aldehydes like furfural and 5-hydroxymethyl-2-furfural to form 2:1 adducts, which are toxic and inefficient due to the need for large quantities of HbS modification.
Innovation Solution
Development of 1:1 adducts of sickle hemoglobin (HbS) with a compound of formula (I), which form a conformationally stable adduct that inhibits the sickled configuration of HbS at lower, safer doses, allowing for effective treatment and improved oxygen affinity without the need for a second compound binding.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If 2:1 adducts are formed using five-membered aldehydes (furfural, 5HMF) to inhibit sickling, then sickle cell disease is treated, but the required doses are unacceptably high and potentially toxic
Solution Approach 1:
The patent changes the stoichiometric parameter from 2:1 (two aldehyde molecules per HbS protein) to 1:1 (one aldehyde molecule per HbS protein). This parameter change allows the compound to bind to a single site on HbS, forming a stable 1:1 adduct that inhibits sickling at lower, safer doses without the toxicity associated with high-dose 2:1 adduct formation
2Reliability
If 2:1 adducts are formed with HbS protein, then sickling is inhibited, but the enormous quantity of HbS protein must be modified requiring high doses
Solution Approach 1:
The patent changes the binding stoichiometry from 2:1 to 1:1, meaning one aldehyde molecule binds to one HbS protein at a specific site. This parameter change increases the efficiency of HbS modification, requiring significantly lower doses of the aldehyde compound to achieve the same therapeutic effect of inhibiting sickling
3Reliability
If 2:1 adducts are formed, then HbS modification occurs, but the need for a second compound binding reduces efficiency
Solution Approach 1:
The patent extracts the second aldehyde molecule from the 2:1 adduct formation mechanism. By identifying a single high-affinity binding site on HbS that accommodates one aldehyde molecule, the patent eliminates the need for a second compound to bind, thereby improving the efficiency and simplifying the mechanism of HbS modification
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The 1:1 adducts effectively inhibit the formation of sickled HbS in vivo, reducing toxicity and increasing oxygen affinity at lower concentrations, providing a safer and more efficient treatment for sickle cell disease.
Implementation Method 1
These aldehydes, such as FUF and 5HMF, act by forming Schiff bases with HbS. Specifically, two molecules of FUF or 5HMF bind to each HbS protein by forming two Schiff base adducts
Data Source
AI summary
Provide herein are 1:1 adducts of sickle hemoglobin (HbS) and a compound of formula (I), as defined herein, suitable as modulators of HbS, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.